Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: JAMA. 2010 Nov 3;304(17):1903–1911. doi: 10.1001/jama.2010.1510

Figure 2.

Figure 2

Change in Primary and Secondary Outcome Measures in the Alzheimer’s Disease Cooperative Study (ADCS) Docosahexaenoic Acid (DHA) Supplementation Trial

All randomized participants were included in these intention-to-treat analyses. Error bars indicate 95% confidence intervals. There was no effect of DHA on rate of cognitive change on the Alzheimer’s Disease Assessment Scale (ADAS; linear mixed-effects model: P = .41), Clinical Dementia Rating (CDR) sum of boxes (linear mixed-effects model: P = .68), ADCS activities of daily living scale (linear mixed-effects model: P = .38), or Neuropsychiatric Inventory (NPI; linear mixed-effects model: P = .11). Scores for the ADAS-cog and CDR sum of boxes were the prespecified primary outcome measures; others were secondary outcomes.